Govt cracks down on GLP-1 drugs: Safety first amid weight-loss hype

India's government has released strict rules for GLP-1 drugs, used for diabetes and obesity. These powerful medications are now prescription-only, requiring specialist doctors. Unsupervised sales are banned. Inspections are increasing, with penalties for rule-breakers. Patients must use these drugs only under medical care to avoid side effects. This move ensures safe use and protects public health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tRfbqPg
via IFTTT

Read More

'Allocate key chemicals to avert drug shortages', says Pharmexcil amid West Asia war

Indian drug makers face a critical shortage of essential raw materials. Pharmexcil has asked the government to divert supplies of propylene, methanol, ammonia, and butane. These are vital for producing solvents and active pharmaceutical ingredients. Low inventories at solvent manufacturers threaten medicine availability. The government is considering quotas to support the pharma sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AkzbDuo
via IFTTT

Read More

Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge generics

Novo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments more accessible to patients. Industry experts believe this will significantly impact competition. Novo Nordisk's established reputation with doctors is also expected to help. The company hopes to gain a larger share of the GLP-1 market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jJXkrHD
via IFTTT

Read More

Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% as GLP-1 competition intensifies in India

Novo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patient access. These new prices, effective April 1, aim to make the GLP-1 therapies more affordable for individuals managing diabetes and obesity. This move comes as Indian companies launch generic semaglutide following patent expiry, intensifying market competition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6dhBEot
via IFTTT

Read More

Lupin gets tentative nod from USFDA for generic Sugammadex injection

Lupin Ltd, a prominent name in the pharmaceutical world, revealed on Tuesday that it has gained tentative approval from the US health authorities for its generic Sugammadex injection. This innovative solution serves to reverse the impacts of muscle relaxants administered during surgeries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SNlPyBz
via IFTTT

Read More

Novo Nordisk plans to cut price of Ozempic as generics hit market

Novo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmakers launched cheaper generic versions of semaglutide. Industry sources suggest Novo's revised price will be competitive. This strategy aims to capture a larger market share against aggressive pricing from Indian companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/raAu7Yq
via IFTTT

Read More

Centre looks to trigger 'Essentials' Act to regulate prices of bulk drugs

The department of pharmaceuticals (DoP) has been holding meetings with the industry executives to take stock of the situation, people in the know said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Vf3cmQN
via IFTTT

Read More